OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
00290159

Double Medical Technology Inc

Medical Equipment, Supplies & DistributionVerified

Double Medical Technology Inc maintains a strong liquidity position with a current ratio of 3.8, indicating the company can cover its short-term liabilities more than three times over. However, the company's cash and equivalents of CNY 4,997,830 are significantly lower than its long-term debt of CNY 315,869,160, resulting in a net cash position that is negative after subtracting total debt. This suggests potential liquidity risk if the company faces unexpected cash outflows or if its operating cash flow does not meet expectations. The company's profitability is robust, with a return on equity (ROE) of 16.8% and a return on assets (ROA) of 12.18%, both exceeding the typical thresholds for strong performance in the medical equipment industry. The gross profit margin of 68.2% (CNY 1,774,706,490 on CNY 2,600,859,750 revenue) and an operating margin of 28.3% (CNY 737,297,850) further support its strong profitability. These metrics suggest the company is effectively managing its costs and generating healthy returns on its operations. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of geographic segmentation may expose the company to regional economic or regulatory risks, particularly if its operations are heavily concentrated in one market. The company's growth trajectory is positive, with a strong operating cash flow of CNY 831,337,040 and a free cash flow of CNY 425,652,810, indicating the ability to fund operations and potentially reinvest in the business. However, the capital expenditure of CNY -133,506,850 suggests a reduction in investment in new assets, which may impact long-term growth if not offset by other strategic initiatives. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The debt-to-equity ratio of 0.09 indicates a conservative capital structure with limited leverage. However, the negative net cash position after subtracting total debt raises concerns about the company's ability to meet long-term obligations without additional financing. The company's ESG score of 28.89 and a C- grade suggest room for improvement in environmental, social, and governance practices. Recent events, as reflected in the company's financial filings, show a consistent revenue and profit performance, with no significant one-time events or extraordinary items reported in the latest financial statements. The company's ESG controversies score of 100 indicates no major controversies, but the low ESG score suggests ongoing challenges in sustainability and governance.

30-day price · 002901-3.34 (-7.6%)
Low$40.00High$45.90Close$40.44As of15 May, 00:00 UTC
Profile
CompanyDouble Medical Technology Inc
Ticker002901.SZ
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Double Medical Technology Inc is a medical equipment and supplies company that generates revenue primarily through the production and distribution of healthcare products.

Classification. The company is classified under the Healthcare Services & Equipment business sector within the Healthcare economic sector, with a classification confidence of 0.92.

Double Medical Technology Inc maintains a strong liquidity position with a current ratio of 3.8, indicating the company can cover its short-term liabilities more than three times over. However, the company's cash and equivalents of CNY 4,997,830 are significantly lower than its long-term debt of CNY 315,869,160, resulting in a net cash position that is negative after subtracting total debt. This suggests potential liquidity risk if the company faces unexpected cash outflows or if its operating cash flow does not meet expectations. The company's profitability is robust, with a return on equity (ROE) of 16.8% and a return on assets (ROA) of 12.18%, both exceeding the typical thresholds for strong performance in the medical equipment industry. The gross profit margin of 68.2% (CNY 1,774,706,490 on CNY 2,600,859,750 revenue) and an operating margin of 28.3% (CNY 737,297,850) further support its strong profitability. These metrics suggest the company is effectively managing its costs and generating healthy returns on its operations. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of geographic segmentation may expose the company to regional economic or regulatory risks, particularly if its operations are heavily concentrated in one market. The company's growth trajectory is positive, with a strong operating cash flow of CNY 831,337,040 and a free cash flow of CNY 425,652,810, indicating the ability to fund operations and potentially reinvest in the business. However, the capital expenditure of CNY -133,506,850 suggests a reduction in investment in new assets, which may impact long-term growth if not offset by other strategic initiatives. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The debt-to-equity ratio of 0.09 indicates a conservative capital structure with limited leverage. However, the negative net cash position after subtracting total debt raises concerns about the company's ability to meet long-term obligations without additional financing. The company's ESG score of 28.89 and a C- grade suggest room for improvement in environmental, social, and governance practices. Recent events, as reflected in the company's financial filings, show a consistent revenue and profit performance, with no significant one-time events or extraordinary items reported in the latest financial statements. The company's ESG controversies score of 100 indicates no major controversies, but the low ESG score suggests ongoing challenges in sustainability and governance.
Key takeaways
  • Double Medical Technology Inc has a strong profitability profile with ROE of 16.8% and ROA of 12.18%.
  • The company's liquidity is robust with a current ratio of 3.8, but its net cash position is negative after subtracting total debt.
  • The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
  • The company's ESG score of 28.89 and a C- grade indicate room for improvement in sustainability and governance practices.
  • The company's capital expenditure is negative, suggesting a reduction in investment in new assets.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$2.60B
Gross profit$1.77B
Operating income$737.3M
Net income$599.6M
R&D
SG&A
D&A
SBC
Operating cash flow$831.3M
CapEx-$133.5M
Free cash flow$425.7M
Total assets$4.92B
Total liabilities$1.35B
Total equity$3.57B
Cash & equivalents$5.0M
Long-term debt$315.9M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$2.60B$737.3M$599.6M$425.7M
FY-1$2.14B$429.1M$356.8M$122.4M
FY-2$1.53B$103.2M$59.0M-$116.9M
FY-3$1.43B$146.9M$92.6M-$289.4M
FY-4$1.99B$802.9M$673.3M$203.1M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$4.92B$3.57B$5.0M
FY-1$4.42B$3.08B$3.6M
FY-2$4.64B$3.06B$949.6M
FY-3$3.94B$3.00B$778.5M
FY-4$3.38B$2.51B
PeriodOCFCapExFCFSBC
FY0$831.3M-$133.5M$425.7M
FY-1$442.3M-$270.5M$122.4M
FY-2$73.9M-$305.7M-$116.9M
FY-3$128.4M-$285.1M-$289.4M
FY-4$673.3M-$235.1M$203.1M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$641.5M$184.7M$146.6M
FQ-1$724.6M$223.3M$175.0M
FQ-2$665.8M$215.7M$180.4M
FQ-3$660.1M$170.4M$141.2M
FQ-4$550.3M$128.3M$103.1M
FQ-5$606.3M$141.0M$116.9M
FQ-6$565.1M$124.6M$101.6M
FQ-7$536.8M$87.5M$76.5M
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$5.03B$3.72B$1.18B
FQ-1$4.92B$3.57B$5.0M
FQ-2$4.55B$3.34B$992.2M
FQ-3$4.36B$3.14B
FQ-4$4.47B$3.19B$993.0M
FQ-5$4.42B$3.08B$3.6M
FQ-6$4.46B$3.16B$1.01B
FQ-7$4.48B$3.09B
PeriodOCFCapExFCFSBC
FQ0$70.4M-$39.3M
FQ-1$831.3M-$133.5M
FQ-2$468.3M-$88.6M
FQ-3$262.8M-$58.2M
FQ-4$25.9M-$28.1M
FQ-5$442.3M-$270.5M
FQ-6$208.8M-$215.6M
FQ-7$133.9M-$142.1M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$3.57B
Net cash-$310.9M
Current ratio3.8
Debt/Equity0.1
ROA12.2%
ROE16.8%
Cash conversion1.4%
CapEx/Revenue-5.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
Metric002901Activity
Op margin28.3%13.3% medp25 5.9% · p75 13.5%top quartile
Net margin23.1%8.6% medp25 2.7% · p75 12.7%top quartile
Gross margin68.2%64.0% medp25 60.1% · p75 65.6%top quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-5.1%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity9.0%69.3% medp25 63.4% · p75 74.5%bottom quartile
Observations
IR observations
market data ESG Score28.89 (0-100, higher is better)
Environment pillar0.97 (0-100)
Social pillar13.59 (0-100)
Governance pillar62.07 (0-100)
ESG controversies score100 (0-100, higher = fewer controversies)
ESG gradeC-
Source: analysis-pipeline (hybrid)Generated: 2026-05-18 00:31 UTCJob: 4834fc5c